BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.16.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Carb-X
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20170312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20171105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20180911T110000
DTEND;TZID=America/New_York:20180911T120000
DTSTAMP:20180829T152008Z
CREATED:20180829T152008Z
LAST-MODIFIED:20180829T152008Z
UID:1770-1536663600-1536667200@carb-x.org
SUMMARY:Antibacterial drugs: Clinical development for non-developers Webinar
DESCRIPTION:Part 2: Development of antibacterial drugs targeting specific pathogens \nThe overall goal of this series of webinars is to provide\, for the non-clinical developer\, an understanding of the risks of development for various kinds of antibacterial products. Our first webinar was devoted to more traditional approaches (Tiers A and B)\, best suited for more broad-spectrum products\, where the risks are lower. In this webinar\, we will discuss the development of products that target a single species of bacteria where the risks may be higher. While development of therapies for infections caused by a single bacterial species that is identified relatively frequently at a given body site of infection (e.g. Staphylococcus aureus (or even MRSA) in acute bacterial skin and skin structure infections) makes for readily feasible trials\, this is not the case for infrequently occurring infections such as those caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Under these circumstances\, a clinical development program can be very challenging. This webinar will give an overview of the practical challenges associated with developing a therapy for a low frequency event for which treatment must be initiated urgently. The presentation will be followed by an interactive Q&A session. \n 
URL:https://carb-x.org/event/antibacterial-drugs-clinical-development-for-non-developers-webinar/
LOCATION:Webinar
END:VEVENT
END:VCALENDAR